Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$58.3 million.

  • Centessa Pharmaceuticals' Cash from Operations fell 17262.61% to -$58.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.8 million, marking a year-over-year decrease of 3875.91%. This contributed to the annual value of -$142.1 million for FY2024, which is 1140.5% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Cash from Operations stood at -$58.3 million for Q3 2025, which was down 17262.61% from -$22.5 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Cash from Operations peaked at -$21.4 million during Q3 2024, and registered a low of -$59.9 million during Q2 2022.
  • Its 4-year average for Cash from Operations is -$42.7 million, with a median of -$42.8 million in 2024.
  • Examining YoY changes over the last 5 years, Centessa Pharmaceuticals' Cash from Operations showed a top increase of 4467.23% in 2025 and a maximum decrease of 17262.61% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Cash from Operations (Quarter) stood at -$51.6 million in 2022, then skyrocketed by 39.78% to -$31.0 million in 2023, then plummeted by 37.84% to -$42.8 million in 2024, then crashed by 36.24% to -$58.3 million in 2025.
  • Its Cash from Operations stands at -$58.3 million for Q3 2025, versus -$22.5 million for Q2 2025 and -$57.2 million for Q1 2025.